We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from intern... A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue. Show more
Ask ADVFN Intelligence (AI)
Cancer, a complex disease characterized by uncontrolled cell growth and proliferation, is often rooted in defects within DNA repair mechanisms. Normally, cells possess intricate To read the full...
A Paris-based healthcare company saw an insanely bullish session on Wednesday after it was announced that AstraZeneca
Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of...
Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data for ULTOMIRIS in generalized myasthenia gravis Patients who transitioned from...
Partnership contributes to the AZ Forest global initiative to plant and maintain 50 million trees worldwide by the end of 2025 AstraZeneca has partnered with The National Fish and Wildlife...
First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs New preclinical authentic ‘live’ virus data from Washington...
First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo’s ENHERTU offer potential to redefine how the disease is classified and treated Positive high-level...
Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful...
Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and...
A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
georgie18
4 minutes ago
georgie18
5 minutes ago
MartinLutherKing
5 minutes ago
Destiny Defined
5 minutes ago
gp22
5 minutes ago
GigantorX
5 minutes ago
gp22
5 minutes ago
ksquared
6 minutes ago
TenKay
6 minutes ago
RIGATONI
6 minutes ago
PickStocks
6 minutes ago
rack186
6 minutes ago
Double DD
6 minutes ago
NoMoDo
6 minutes ago
vlispxpert
6 minutes ago
koolmc
7 minutes ago
pinkslipjunkie
7 minutes ago
i_like_bb_stock
7 minutes ago
i_like_bb_stock
7 minutes ago
JTORENCE
7 minutes ago
SPANISH_gladiator
8 minutes ago
Tr8dervic
8 minutes ago
Porch Honkey
8 minutes ago
DiscoverGold
8 minutes ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
